[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355906-105":59,"doc-detail-355906-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","biomarker-study-of-pembrolizumab-in-patients-with-advanced-rare-cancers","Biomarker study of pembrolizumab in patients with advanced rare cancers","","Rare cancers often lack robust, evidence-based treatment options. This prospective, multi-histology phase 2 trial evaluates pembrolizumab in 154 patients (142 evaluable), reporting an objective response rate of 14.8% and clinical benefit in 26.8%. Multi-modal profiling uses baseline, on-treatment, and progression samples. Clinical benefit associates with MSI-H/TMB-H and PD-L1 CPS ≥10, but also occurs in biomarker-negative tumors. Benefit corresponds to higher pre-treatment immune infiltration and T-cell activation, while non-benefit shows proliferative programs, with treatment-induced immune activation in moderately infiltrated tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biomarker-study-of-pembrolizumab-in-patients-with-advanced-rare-cancers/355906/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biomarker-study-of-pembrolizumab-in-patients-with-advanced-rare-cancers/355906.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What did the prospective phase 2 trial evaluate and how many patients were included?","Question",{"text":112,"@type":113},"The trial evaluated pembrolizumab in advanced rare cancers using a prospective, multi-histology phase 2 design. It included 154 patients, with 142 evaluable for outcome assessment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers were associated with clinical benefit, and what limitation was noted?",{"text":117,"@type":113},"Clinical benefit associated with high MSI-H/high TMB-H and with PD-L1 CPS ≥10. The document notes these biomarkers explain only a small subset of the observed clinical benefit.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the immune microenvironment differ between clinical benefit and non-benefit tumors?",{"text":121,"@type":113},"Clinical benefit tumors showed higher pre-treatment immune infiltration and T-cell activation. Non-benefit tumors showed proliferative programs, and moderately infiltrated tumors exhibited increased immune content during treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355906,1790177461,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Article  \nBiomarker study of pembrolizumab in patients with advanced rare cancers  \nGraphical abstract  \nHighlights  \n• Pembrolizumab achieved clinical benefit across multiple advanced rare cancer types  \nAuthors  \nAung Naing, Xiqi Li, Qi Wang, ..., Jing Wang, Scott Eric Woodman, Funda Meric-Bernstam  \nCorrespondence  \n[anaing@mdanderson.org](anaing@mdanderson.org)  \nIn brief  \nNaing et al. study pembrolizumab in advanced rare cancers and show that immune contexture, rather than genomic biomarkers alone, associates with clinical benefit, with responses enriched by MSIH/TMB-H and driven by pre-existing or treatment-induced immune activation in moderately infiltrated tumors.  \n• MSI-H/TMB-H enrich for response but explain only a small subset of clinical benefit  \n• Intermediate infiltration tumors respond via treatmentinduced immune activation  \n• Multi-model profiling reveals immune contexture as a key determinant of response  \nNaing et al., 2026, Cell Reports Medicine 7, 102827  \nJune 16, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102827](https://doi.org/10.1016/j.xcrm.2026.102827)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nBiomarker study of pembrolizumab in patients with advanced rare cancers  \nAung Naing,1,10,* Xiqi Li,2 Qi Wang,3 Xiangjun (Jun) Tian,3 Sharjeel Sabir,4 Priya R. Bhosale,5 Mohamed H. Derbala,1  \nBettzy Stephen,1 Mingxuan Xu,1 Joud Hajjar,6 Serdar A. Gurses,1 Yali Yang,1 Hassan Ahmed Momin,1 Ignacio Ivan Wistuba,7 Anas Alshawa,1 Kenna R. Shaw,8 Abdulrazzak Zarifa,1 Gopal Singh,1 Renganayaki Krishna Pandurengan,7 Gabriela Maria Raso,7 Edwin Roger Parra,7 Juhee Song,9  \nMohammad Moustaf Mohammad,8 Jordi Rodon Ahnert,1 Siqing Fu,1 Vivek Subbiah,1 Sarina Anne Piha-Paul,1 Jing Wang,3 Scott Eric Woodman,2 and Funda Meric-Bernstam1  \n1Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n2Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n3Bioinformatics & Comp Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n4Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n5Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n6Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX 77030, USA  \n7Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n8Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n9Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n10Lead contact  \n*Correspondence: [anaing@mdanderson.org](anaing@mdanderson.org)  \n[https://doi.org/10.1016/j.xcrm.2026.102827](https://doi.org/10.1016/j.xcrm.2026.102827)  \nSUMMARY  \nRare cancers lack robust, evidence-based treatment options. We conduct a prospective, multi-histology phase 2 clinical trial of pembrolizumab in 154 patients (142 evaluable) , observing an objective response rate of 14.8% and clinical benefit (CB) in 26.8% . Multi-modal profiling is performed on baseline, on-treatment, and progression samples. CB associates with high microsatellite instability (MSI-H)/high tumor mutation burden (TMB-H) (odds ratio [OR]: 13.9, p = 0.0013) and programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥10 (p = 0.0285), although responses also occur in biomarker-negative tumors and vary by histology. CB tumors exhibit higher pre-treatment immune infiltration and T cell activation, whereas no CB (NCB) tumors show proliferative programs. In moderately infiltrated tumors, CB associates with increased immune content during treatment. Multiplex immunofluorescence confirms higher baseline T cell densities in CB and limited remodeling in NCB tumors. These findings suggest that tu","cbCaibCYRMqiFqnH","https://ap.wps.com/l/cbCaibCYRMqiFqnH","pdf",4322368,15,"English","# Summary\n## Clinical trial design and endpoints\n## Biomarker associations and response patterns\n## Immune microenvironment and T-cell activation\n## Implications for predictive markers","[{\"question\":\"What did the prospective phase 2 trial evaluate and how many patients were included?\",\"answer\":\"The trial evaluated pembrolizumab in advanced rare cancers using a prospective, multi-histology phase 2 design. It included 154 patients, with 142 evaluable for outcome assessment.\"},{\"question\":\"Which biomarkers were associated with clinical benefit, and what limitation was noted?\",\"answer\":\"Clinical benefit associated with high MSI-H/high TMB-H and with PD-L1 CPS ≥10. The document notes these biomarkers explain only a small subset of the observed clinical benefit.\"},{\"question\":\"How did the immune microenvironment differ between clinical benefit and non-benefit tumors?\",\"answer\":\"Clinical benefit tumors showed higher pre-treatment immune infiltration and T-cell activation. Non-benefit tumors showed proliferative programs, and moderately infiltrated tumors exhibited increased immune content during treatment.\"}]","Biomarker study of pembrolizumab in patients with advanced rare cancers | PDF",1790121670,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed77bf9fa0a6e430995ceddaca87122a.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec410b36c0f1aaebc91a8aab621436b5.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b2b0e44a617cdc6869f8144154c5a3c.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fa96061abb5e95c034af39bd3f2736b.webp",980,1272]